Ana Beltrán Arranz

Dr. Ana Beltrán Arranz


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2024 in Science Advances
Verified
Journal Article
Open access
NMNicolás Marichal
Nicolás Marichal
SPSophie Péron
Sophie Péron
AAAna Beltrán Arranz
Ana Beltrán Arranz
CGChiara Galante
Chiara Galante
FSFranciele Franco Scarante
Franciele Franco Scarante
BBBenedikt Berninger
Benedikt Berninger
Cellular reprogramming of mammalian glia to an induced neuronal fate holds the potential for restoring diseased brain circuits. While the proneural factor achaete-scute complex-like 1 ( Ascl1 ) is widely used for neuronal reprogramming, in the early postnatal mouse cortex, Ascl1 fails to induce the glia-to-neuron conversion, instead promoting the proliferation of oligodendrocyte progenitor cells (OPC). Since Ascl1 activity is posttranslationally regulated, here, we investigated the consequences of mutating six serine phospho-acceptor sites to alanine (Ascl1SA6) on lineage reprogramming in vivo. Ascl1SA6 exhibited increased neurogenic activity in the glia of the early postnatal mouse cortex, an effect enhanced by coexpression of B cell lymphoma 2 ( Bcl2 ). Genetic fate-mapping revealed that most induced neurons originated from astrocytes, while only a few derived from OPCs. Many Ascl1SA6/Bcl2-induced neurons expressed parvalbumin and were capable of high-frequency action potential firing. Our study demonstrates the authentic conversion of astroglia into neurons featuring subclass hallmarks of cortical interneurons, advancing our scope of engineering neuronal fates in the brain.

4 November 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
NMNicolás Marichal
Nicolás Marichal
SPSophie Péron
Sophie Péron
AAAna Beltrán Arranz
Ana Beltrán Arranz
CGChiara Galante
Chiara Galante
FSFranciele Franco Scarante
Franciele Franco Scarante
BBBenedikt Berninger
Benedikt Berninger
Cellular reprogramming of mammalian glia to an induced neuronal fate holds potential for restoring diseased brain circuits. While the proneural factor Ascl1 is widely used for neuronal reprogramming, in the early postnatal mouse cortex Ascl1 fails to induce glia-to-neuron conversion, instead promoting proliferation of oligodendrocyte progenitor cells (OPC). Since Ascl1 activity is post-translationally regulated, here we investigated the consequences of mutating six serine phospho-acceptor sites to alanine (Ascl1SA6) on lineage reprogramming in vivo . Ascl1SA6 exhibited increased neurogenic activity in glia of the early postnatal mouse cortex, an effect enhanced by co-expression of Bcl2. Genetic fate-mapping revealed that most induced neurons originated from astrocytes while only a few derived from OPCs. Intriguingly, many Ascl1SA6/Bcl2-induced neurons expressed parvalbumin and were capable of high-frequency action potential firing. Our study demonstrates authentic conversion of astroglia into neurons featuring subclass hallmarks of cortical interneurons, advancing our scope of engineering neuronal fates in the brain.

14 April 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
YCYolanda Castellote-Caballero
Yolanda Castellote-Caballero
AAAna Beltrán Arranz
Ana Beltrán Arranz
Agustín Aibar-AlmazánAgustín Aibar-Almazán
Agustín Aibar-Almazán
MCMaría del Carmen Carcelén-Fraile
María del Carmen Carcelén-Fraile
YRYulieth Rivas-Campo
Yulieth Rivas-Campo
AGAna Maria González-Martín
Ana Maria González-Martín
Background/Objectives: A mango (Mangifera indica) leaf extract (Zynamite®), rich in the polyphenol mangiferin, has been demonstrated to modulate brain activity, boost cognitive function, and reduce mental fatigue. Research evidence supports that improving the solubility of this extract could significantly enhance its efficacy as an active ingredient. This study examined the effects of a soluble version of Zynamite®, Zynamite® S (Zyn-S), on cognitive function and mood in young adults at low doses. Methods: A total of 119 university students were enrolled in the study. Participants were randomly assigned to receive either 100 mg, 150 mg, or placebo in a double-blind crossover design. Short- and long-term memory were evaluated using the Rey Auditory Verbal Learning Test (RAVLT), executive functions with the Trail Making Test (TMT), processing speed with the Digit Symbol Substitution Test (DSST), and selective attention with the Stroop Color and Word Test. Additionally, mood was assessed using the Spanish short version of the Profile of Mood States (POMS). All these assessments were conducted before taking the product and at 30 min, 3 h, and 5 h post-intake. Results: The results demonstrated that participants who received Zynamite® S experienced significant improvements in reduced tension, depression, and confusion, suggesting an enhancement in mental clarity and overall emotional well-being. Both interventions also improved processing speed and cognitive flexibility. However, no significant differences were observed in short- and long-term verbal memory. Conclusions: In summary, these findings support Zynamite® S as a natural nootropic capable of acutely improving key cognitive functions and emotional balance at low doses in young adults, with sustained efficacy for at least five hours.

27 January 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
SLSydney Leaman
Sydney Leaman
FFFilipe Machado Ferreira
Filipe Machado Ferreira
LDLin Dong
Lin Dong
AAAna Beltrán Arranz
Ana Beltrán Arranz
JJJerónimo Jurado-Arjona
Jerónimo Jurado-Arjona
BBBenedikt Berninger
Benedikt Berninger
Inducing neurogenesis from glia could permit circuit remodeling and neuron replacement in the brain. Indirect evidence suggests that glia-to-neuron reprogramming is feasible, but the dynamics of conversion have not been directly observed, and it remains unclear whether glia-derived cortical neurons can functionally integrate into brain circuits. Here, we use two-photon imaging to visualize the reprogramming of astroglia into induced neurons in the mouse cortex in vivo . We track the emergence of spontaneous neuron-like calcium transients in astrocyte-derived induced neurons, demonstrating their functional activity in vivo . Importantly, these induced neurons exhibit orientation tuned, visually evoked calcium responses, demonstrating their functional integration into cortical circuitry - a prerequisite for their utility in circuit repair. Thus, astrocytes can be recruited to generate functional neurons in the postnatal cortex, enabling circuit remodeling in perinatal injury or neurodevelopmental disorders without relying on external cellular sources.

18 July 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
AAAna Beltrán Arranz
Ana Beltrán Arranz
Agustín Aibar-AlmazánAgustín Aibar-Almazán
Agustín Aibar-Almazán
DRdavid fuentes rios
david fuentes rios
RMRubén Pérez Machín
Rubén Pérez Machín
MCMaría del Carmen Carcelén-Fraile
María del Carmen Carcelén-Fraile
MCMaría Yolanda Castellote-Caballero
María Yolanda Castellote-Caballero
Background/Objectives: Botanical nootropics are increasingly sought as natural alternatives to synthetic stimulants. Mangifera indica leaf extract, standardized to the polyphenol mangiferin, has shown promise in regulating brain activity and enhancing cognitive performance. This study aimed to replicate, in an independent cohort, the acute cognitive benefits of a soluble mango leaf extract (Zynamite® S) following a previous proof-of-concept trial. Methods: In a double-blind, randomized, placebo-controlled crossover trial, 88 healthy young adults (aged 18–25) received either a single 100 mg dose of Zynamite® S or a matched placebo. Cognitive performance was assessed using the Trail Making Test (TMT), Digit Symbol Substitution Test (DSST), and Stroop Color-Word Test. Emotional states were assessed via the Profile of Mood States (POMS) at baseline, and then at 30 min, 3 h, and 5 h post-ingestion. Results: Zynamite® S supplementation resulted in the replication of previous findings, with significant improvements in mental processing speed, attention, and cognitive flexibility (p < 0.05). Notably, this trial identified a rapid onset of action, with significant cognitive and mood improvements detectable as early on as 30 min post-dose and a sustained duration of the effect with benefits observed up to 5 h post-administration. Mood assessments confirmed an overall improvement in emotional balance (p < 0.05) by reducing tension, mental fatigue, and low mood during the completion of cognitive-demanding tasks. Conclusions: These findings reproduce the acute benefits of Zynamite® S in a healthy young adult population, including a rapid onset of effects and a sustained improvement in cognitive performance and mood over a 5 h window.